Susquehanna International Group, LLP Akebia Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $688 Billion
- Q2 2025
A detailed history of Susquehanna International Group, LLP transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 791,352 shares of AKBA stock, worth $2.63 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
791,352
Previous 687,279
15.14%
Holding current value
$2.63 Million
Previous $1.32 Million
118.35%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding AKBA
# of Institutions
171Shares Held
105MCall Options Held
134KPut Options Held
262K-
Vanguard Group Inc Valley Forge, PA14.6MShares$48.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$38.6 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$26.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$20.2 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$19.1 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $610M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...